Thermo Fisher Scientific Inc.
TMO
$472.63
-0.23%
Thermo Fisher Scientific Inc. is a global leader in the healthcare sector, specifically within the medical diagnostics and research industry, providing essential scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents. The company is a dominant, integrated platform player, serving customers across the analytical technologies, specialty diagnostics, life sciences, and lab products and services segments, which gives it a unique competitive moat through its scale and breadth of offerings. The current investor narrative revolves around the company's ability to demonstrate operational resilience and deliver steady growth in a post-pandemic normalization phase, as highlighted by its recent strong quarterly results and raised long-term guidance, while simultaneously navigating new macroeconomic pressures such as inflation and geopolitical tensions.…
TMO
Thermo Fisher Scientific Inc.
$472.63
TMO 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $614.42 and implied upside of +30.0% versus the current price.
Average Target
$614.42
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$378 - $614
Analyst target range
Analyst coverage for TMO is robust, with 7 analysts providing estimates, and the institutional sentiment is overwhelmingly bullish, as evidenced by recent actions from firms like Citigroup and Keybanc upgrading to 'Buy' and 'Overweight' in December 2025. The consensus recommendation, inferred from the institutional ratings, is a 'Buy' or 'Overweight', with an average revenue estimate of $58.18 billion and an average EPS estimate of $37.78 for the forward period, though a specific consensus price target is not provided in the data. The target price range can be inferred from the estimated EPS range of $36.89 (low) to $38.22 (high); applying the forward PE of 17.22x suggests an implied price target range of approximately $635 to $658, which would represent a substantial 35% to 40% upside from the current price of $469.34, signaling strong analyst conviction in a recovery. The wide implied target range, based on EPS estimates, reflects differing assumptions about the company's ability to navigate inflationary pressures and return to its historical growth trajectory, with the high end likely pricing in successful execution of raised long-term guidance and margin expansion, while the low end may factor in prolonged macroeconomic headwinds.
TMO Technical Analysis
The stock is in a pronounced downtrend, having declined 17.99% over the past six months and 20.79% year-to-date as of the current date. Trading at a price of $469.34, the stock sits approximately 27% above its 52-week low of $385.46 but 27% below its 52-week high of $643.99, indicating it is in the lower-middle portion of its annual range, which suggests the downtrend has created a potential value zone but with significant technical damage. Recent short-term momentum shows a modest 5.23% gain over the past month, which conflicts with the longer-term negative trends and could signal a tentative stabilization or oversold bounce; however, this is juxtaposed against a stark underperformance relative to the market, evidenced by a 1-month relative strength of +5.31% versus the S&P 500's -0.08% but a deeply negative 1-year relative strength of -9.86%. Key technical levels are clearly defined, with major support at the 52-week low of $385.46 and immediate resistance at the recent recovery high near $527.22 from mid-April; a sustained break below support would signal a continuation of the bearish trend, while a move above the $520-$530 zone could indicate a more durable recovery is underway. The stock's beta of 0.87 indicates it has been less volatile than the broader market during this decline, which is atypical for a downtrend of this magnitude and may suggest the selling pressure has been more systematic than stock-specific.
Beta
0.87
0.87x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$385-$644
Price range past year
Annual Return
+16.7%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +7.8% | +1.5% |
| 3m | +1.7% | +13.4% |
| 6m | -16.0% | +10.9% |
| 1y | +16.7% | +24.5% |
| ytd | -20.2% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Revenue growth remains positive but has moderated from pandemic-era peaks, with the most recent Q4 2025 revenue of $12.22 billion representing a 7.2% year-over-year increase; this growth rate, while solid, reflects a normalization trend as the multi-quarter sequential revenue build from $10.36B in Q1 to $12.22B in Q4 shows consistent execution, though segment data indicates the consumables business ($5.03B) and service segment ($4.97B) are the primary revenue drivers, underscoring the company's resilient recurring revenue model. Profitability is robust, with the company generating a net income of $1.98 billion in Q4 2025 and a trailing net margin of 15.12%; gross margin for the quarter was 37.95%, which is consistent with the trailing gross margin of 37.66%, indicating stable pricing power and cost management despite inflationary pressures cited in recent news. The balance sheet and cash flow position remain strong, with a manageable debt-to-equity ratio of 0.76, a healthy current ratio of 1.89, and substantial free cash flow generation of $6.29 billion on a trailing twelve-month basis; this robust FCF, which supports a FCF yield of approximately 2.9% based on the current market cap, provides ample flexibility for strategic M&A, share repurchases, and dividends, as evidenced by the $3 billion in stock repurchases and $162 million in dividends paid during Q4 2025.
Quarterly Revenue
$12.2B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.37%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Given the company's consistent profitability with a net income of $1.98 billion in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 32.34x, which is significantly higher than the forward PE of 17.22x, indicating the market expects a substantial recovery in earnings over the next twelve months. Compared to sector averages, the trailing PE of 32.34x represents a significant premium; while specific industry average data is not provided in the valuation data, the elevated level suggests the market continues to price in a quality and growth premium for this industry leader, which may be justified by its scale, margins, and resilient cash flows. Historically, the current trailing PE of 32.34x is above the stock's own historical range evident in the data, which has fluctuated between the mid-20s and low-40s over recent years; trading near the higher end of its own historical band, despite the recent price decline, implies that earnings compression has occurred and the market is still pricing in a return to stronger earnings growth, leaving little margin for error if execution falters.
PE
32.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.7x
Enterprise Value Multiple

